Abstract
Mpox has spread rapidly to many countries in non-endemic regions. After reviewing detailed exposure histories of 109 pairs of mpox cases in the Netherlands, we identified 34 pairs where transmission was likely and the infectee reported a single potential infector with a mean serial interval of 10.1 days (95% CI: 6.6–14.7 days). Pre-symptomatic transmission may have occurred in five out of eighteen pairs. These findings emphasize that precaution remains key, regardless of the presence of recognizable symptoms of mpox.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was financed by the Netherlands Ministry of Health, Welfare and Sport. FM acknowledges funding from Japan Society for the Promotion of Science (JSPS KAKENHI, Grant Number 20J00793).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Centre for Clinical Expertise (CCE) at the RIVM (Netherlands Institute for Public Health and the Environment) is the official body in our Institute, responsible for advice and oversight on human-related research. The CCE assessed the research presented in this paper, and verified whether the work complies with the specific conditions as stated in the law for medical research involving human subjects (WMO). The CCE is of the opinion that the research does not fulfill one or both of these conditions and therefore concludes that it is exempted for further approval by the ethical research committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The author list is updated
Data Availability
Anonymized data and all codes used for analysis and visualization are available on Github (https://github.com/fmiura/MpxSI_2022).
